Pfizer diabetes and obesity study triggers Sosei Heptares windfall
Sosei Group Corporation has been notified by Pfizer that the first subject in a phase…
December 21, 2022 - 3 minutes
Sosei Heptares
Sosei Heptares and Lilly enter agreement on diabetes and metabolic diseases
Sosei Group Corporation has entered a drug discovery collaboration with Eli Lilly and Company to…
December 16, 2022 - 2 minutes
Sosei Heptares signs R&D agreements on gastrointestinal and immune disorders
Sosei Heptares has entered translational medicine and R&D agreements with the MRC Weatherall Institute of…
December 8, 2022 - 3 minutes
PrecisionLife supports Sosei Heptares to treat chronic diseases in more personalized way
PrecisionLife, developers of precision medicine for chronic diseases, will be supporting biopharmaceutical group, Sosei Heptares,…
November 9, 2022 - 3 minutes
Neurocrine to conduct placebo-controlled study to investigate potential new treatment for schizophrenia
A phase 2 clinical trial for the treatment of schizophrenia has been accepted by the…
August 5, 2022 - 3 minutes
Sosei Heptares and AbbVie enter second collaboration targeting neurological diseases
A new drug discovery collaboration has taken place between Japanese Sosei Group Corporation and UK-based…
August 2, 2022 - 2 minutes
